Effect of mazindol on dopamine transporter

Effect of mazindol on dopamine transporter - Effect of mazindol on DAT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008232

Enrollment

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy male subjects

Interventions

1.5 mg of mazindol p.o. [C-11]raclopride PET and [F-18]FE-PE2I PET

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy volunteers who do not have any psychiatric disorders or serious medical illnesses and who are able to understand an explanatory document and give consent are included in this study

Exclusion criteria

Exclusion criteria: -Psychiatric disorders including drug dependence -Serious medical illness

Design outcomes

Primary

Measure	Time frame
Binding of clinical dose of mazindol to dopamine transporter	—

Secondary

Measure	Time frame
1. Effect of clinical dose of mazindol on dopamine release 2. Effect of clinical dose of mazindol on cerebral blood flow and cognitive functions	—

Countries

Japan

Contacts

Public ContactKazuko Suzuki

National Institute of Radiological Sciences clinical research support unit

volunteer@nirs.go.jp043-206-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026